<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14165">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02922478</url>
  </required_header>
  <id_info>
    <org_study_id>28-476 ex 15/16</org_study_id>
    <nct_id>NCT02922478</nct_id>
  </id_info>
  <brief_title>Role of Comorbidities in Chronic Heart Failure Study</brief_title>
  <acronym>RoC-HF</acronym>
  <official_title>Role of Comorbidities in Chronic Heart Failure (RoC-HF) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to create a database of patients with stable and chronic heart failure with
      comprehensive assessment of bone, skeletal and vascular status. RoC-HF will facilitate
      cross-sectional and, eventually, longitudinal mechanistic epidemiological analyses to
      disentangle the role of the bone- vascular axis in chronic heart failure. Blood and urine
      samples will be stored to facilitate future biomarker analyses.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Week</target_duration>
  <primary_outcome>
    <measure>Prevalence of osteoporosis in chronic heart failure</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Prevalence of vertebral fractures in chronic heart failure</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral and central pulse wave velocity</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>24-hours systolic and diastolic blood pressure</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Heart Failure</condition>
  <condition>Comorbidity</condition>
  <condition>Osteoporosis</condition>
  <condition>Pulse Wave Analysis</condition>
  <condition>Blood Pressure Monitoring, Ambulatory</condition>
  <condition>Osteoporotic Fractures</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>X-ray of the spine</intervention_name>
    <description>Every participant will undergo X-ray of the spine so that vertebral fractures can be quantified using the Genant score.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ambulatory blood pressure monitoring (ABPM)</intervention_name>
    <description>ABPM will be performed using the brachial, oscillometric, automated self-measurement mobil-O-Graph device (I.E.M. GmbH, Stolberg, Germany) with integrated ARCSolver®-Software (Austrian Institute of Technology Wien).</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dual X-ray absorptiometry</intervention_name>
    <description>Individual bone mineral density and T-Score will be determined by X-ray absorptiometry.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Non-invasive procedures</intervention_name>
    <description>Other non-invasive study procedures include structured patient interview, sampling of blood, buffy coat and spot urine (including biobanking), electrocardiogram, pulse wave velocity and analysis, transthoracic echocardiography, 4-meter gait speed test, hand grip test, questionnaires</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA plasma, serum and buffy coat will be stored at -80 °C for later determination of
      biomarkers and DNA sequencing.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stable patients with chronic heart failure
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;= 18

          2. NYHA (New York Heart Association) class II-IV symptoms

          3. Chronic HFrEF (Heart failure with reduced ejection fraction)defined as left
             ventricular ejection &lt; 50% at Visit 1.

          4. Treatment according to current Heart Failure Guidelines of the European Society of
             Cardiology

          5. Willingness and ability to provide signed informed consent form (ICF) prior to
             participation in any study-related procedures

        Exclusion Criteria:

          1. Unplanned hospitalization within 1 month prior to the Baseline Visit.

          2. Discontinuation or initiation of a pharmacologic or device treatment for HFrEF within
             1 month prior to the baseline visit.

          3. Coronary or peripheral revascularization procedures, valvular procedures, OR any
             major surgical procedure within 3 months prior to the Screening Visit.

          4. Acute coronary syndrome (ACS), stroke or transient ischemic attack (TIA) within 3
             months prior to the Screening Visit.

          5. Any acute illness

          6. Disease reducing life expectancy to &lt; 1 year, except HFrEF

          7. Recipient of any organ transplant

          8. Primary significant valve disease (at least moderate to severe valve disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Verheyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klemens Ablasser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 30, 2016</lastchanged_date>
  <firstreceived_date>September 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Dirk von Lewinski</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporotic Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
